NovoCure Limited Stock News

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novocure (NASDAQ:NVCR) is scheduled to issue its quarterly earnings data before the market opens on Thursday, April 30th. Analysts expect the company to announce earnings of $0.06 per share for the qu

A successful cancer treatment for the most invasive type of brain cancer is showing promise in other oncological fields.

Novocure (NASDAQ:NVCR) was downgraded by Evercore ISI from an “in-line” rating to an “underperform” rating in a research report issued to clients and investors on Sunday, Benzinga reports. A n

Equities research analysts at Piper Sandler began coverage on shares of Novocure (NASDAQ:NVCR) in a research report issued on Sunday, Benzinga reports. The brokerage set an “overweight” rating and

Shares of Novocure Ltd (NASDAQ:NVCR) have been assigned an average rating of “Hold” from the twelve research firms that are covering the stock, Marketbeat reports. Two research analysts have rated

Exchange Traded Concepts LLC lifted its stake in shares of Novocure Ltd (NASDAQ:NVCR) by 193.2% during the first quarter, according to the company in its most recent disclosure with the Securities & E

Novocure Ltd (NASDAQ:NVCR) COO Michael J. Ambrogi sold 27,519 shares of the company’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $71.00, for a total v

Ladenburg Thalmann Financial Services Inc. lessened its position in shares of Novocure Ltd (NASDAQ:NVCR) by 6.8% during the fourth quarter, according to its most recent filing with the Securities and

Evercore ISI cut shares of Novocure (NASDAQ:NVCR) from an in-line rating to an underperform rating in a research note issued to investors on Thursday, Benzinga reports. They currently have $58.00 targ

Novocure Ltd (NASDAQ:NVCR) – Piper Sandler issued their Q1 2020 EPS estimates for Novocure in a report issued on Tuesday, April 7th. Piper Sandler analyst J. Bednar anticipates that the medical equi

Fly Intel: Pre-market Movers BHVN BIG OVV NLS SBUX COST CLVS NVCR ANET

Inspire Medical Systems (NYSE:INSP) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler.Prevail Therapeutics (NASDAQ:PRVL) initiated with Overweight rating and $20 (46%

NovoCure Limited (NASDAQ:NVCR), which is in the medical equipment business, and is based in Jersey, saw a decent share...